Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna's lead drug candidate Study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile CAL101 is ...